Arrowhead Pharmaceuticals Prices $753.7M Dual Offering to Fund R&D and Commercialization

summarizeSummary

Arrowhead Pharmaceuticals announced the pricing of a combined equity and convertible senior notes offering, raising approximately $753.7 million in net proceeds to bolster its financial position for general corporate purposes, including R&D and commercialization activities.

check_boxKey Events

• Dual Offering Priced

  The company priced a combined offering of 3,100,776 shares of common stock (or pre-funded warrants) and $625 million aggregate principal amount of 0.00% convertible senior notes due 2032.

• Significant Capital Raise

  The offerings are expected to generate approximately $753.7 million in net proceeds for the company, combining $188.3 million from the equity offering and $565.4 million from the convertible notes (after accounting for capped call costs).

• Equity Offering Details

  3,100,776 shares were offered at $64.50 per share, a slight discount to the last reported sale price of $65.69.

• Convertible Notes Terms

  The $625 million convertible notes bear 0.00% interest, mature in 2032, and have an initial conversion price of approximately $87.07, representing a 35.0% premium over the equity offering price. The company will use a portion of the proceeds to fund capped call transactions to mitigate dilution.

auto_awesomeAnalysis

This significant capital raise provides Arrowhead Pharmaceuticals with substantial funding to advance its pipeline and prepare for potential commercial launches. While the equity component introduces dilution, the overall financing package, particularly the 0.00% convertible notes with a 35% conversion premium and capped call transactions, demonstrates favorable terms for the company. The proceeds will extend the company's operational runway, supporting critical research, development, and commercialization efforts, which is crucial for a life sciences company.